ImmunityBio, Inc.
- Last sale
- Nov 12, 2026 · -9.00%
- Market cap
- $6.45B
- 1.06B shares
- Filings
- 557
Q3 2026+668.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−38.4% FY25 yoy
- $6.45B
- —
- 35.3×
- —
- -4.60%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $113,288,000 | reported | |
| FY 2024 | 2024-12-31 | $14,745,000 | reported | |
| FY 2023 | 2023-12-31 | $622,000 | reported | |
| FY 2022 | 2022-12-31 | $240,000 | reported | |
| FY 2021 | 2021-12-31 | $934,000 | reported | |
| FY 2020 | 2020-12-31 | $605,000 revised | reported | |
| FY 2019 | 2019-12-31 | $2,202,000 revised | reported | |
| FY 2018 | 2018-12-31 | $47,000 | reported | |
| FY 2017 | 2017-12-31 | $45,000 | reported | |
| FY 2016 | 2016-12-31 | $44,000 | reported | |
| FY 2015 | 2015-12-31 | $236,000 | reported | |
| FY 2014 | 2014-12-31 | $641,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2021 | — | $0.00 | $0.00 | — | 397.91M sh | +263.9% | — |
| FY2020 | — | $0.00 | $0.00 | — | 109.34M sh | +11.0% | — |
| FY2019 | — | $2.50M | $2.50M | — | 98.48M sh | +24.5% | — |
| FY2018 | — | $228.00K | $228.00K | — | 79.09M sh | +0.1% | — |
| FY2017 | — | $15.23M | $15.23M | — | 79.03M sh | −4.0% | — |
Segments
LineFY2025ShareChange
U.S.$113.01M100%+695.1%
Europe$278.00K0.2%−47.6%
Total$113.29M
Biological products, except diagnostic substances
ImmunityBio, Inc. is the 29th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
BEAMBeam Therapeutics Inc.$139.7M120.0%57.2%$2.5BGLUEMonte Rosa Therapeutics, Inc.$123.7M63.5%31.2%$793.0MATRAAtara Biotherapeutics, Inc.$120.8M6.3%27.1%$80.4MAGENAgenus Inc$114.2M10.4%2.7%$323.1M
IBRXImmunityBio, Inc. (this company)$113.3M668.3%310.2%$6.5B
IPSCCentury Therapeutics, Inc.$109.2M1,556.8%8.8%$294.2MSTROSutro Biopharma, Inc.$102.5M65.2%186.5%$159.0MFDMT4D Molecular Therapeutics, Inc.$85.2M230,194.6%164.4%$682.1MMGTXMeiraGTx Holdings plc$81.4M144.6%140.3%$858.1MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
ImmunityBio, Inc. · CIK 1326110 · Engraved from SEC EDGAR